Letter: FibroTest for staging fibrosis in non-alcoholic fatty liver disease

Alimentary Pharmacology and Therapeutics

Volumn 37, Issue 6, 2013, Pages 655-656

  Munteanu, M ^a   Ratziu, V ^a   Poynard, T ^a  

^a SORBONNE UNIVERSITÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BIOLOGICAL MARKER;

CLINICAL ASSESSMENT; COMPARATIVE EFFECTIVENESS; DIAGNOSTIC EQUIPMENT; DISEASE CLASSIFICATION; ELASTOGRAPHY; FIB4 SCORE; HEPASCORE; HUMAN; INTERMETHOD COMPARISON; LETTER; LIVER FIBROSIS; META ANALYSIS (TOPIC); NON INVASIVE PROCEDURE; NONALCOHOLIC FATTY LIVER; NONALCOHOLIC FATTY LIVER DISEASE FIBROSIS SCORE; PREDICTIVE VALUE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SCORING SYSTEM; STAGING; VALIDATION STUDY;

FATTY LIVER; HUMANS;

EID: 84874098961     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12219     Document Type: Letter

References (9)

1. Festi D, Schiumerini R, Marzi L, et al,. Review article: the diagnosis of non-alcoholic fatty liver disease-availability and accuracy of non-invasive methods. Aliment Pharmacol Ther 2013; 37: 392-400.
2. Lambert J, Halfon P, Penaranda G, Bedossa P, Cacoub P, Carrat F,. How to measure the diagnostic accuracy of noninvasive liver fibrosis indices: the area under the ROC curve revisited. Clin Chem 2008; 54: 1372-8.
3. Lassailly G, Caiazzo R, Hollebecque A, et al,. Validation of noninvasive biomarkers (FibroTest, SteatoTest, and NashTest) for prediction of liver injury in patients with morbid obesity. Eur J Gastroenterol Hepatol 2011; 23: 499-506.
4. Poynard T, Lassailly G, Diaz E, et al,. Performance of biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in patients with severe obesity: meta analysis of individual patient data. PLoS ONE 2012; 7: e30325.
5. Adams LA, George J, Bugianesi E, et al,. Complex non-invasive fibrosis models are more accurate than simple models in non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2011; 26: 1536-43.
6. Ratziu V, Charlotte F, Heurtier A, et al,.; LIDO Study Group. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005; 128: 1898-906.
7. Poynard T, Lenaour G, Vaillant JC, et al,. Liver biopsy analysis has a low level of performance for diagnosis of intermediate stages of fibrosis. Clin Gastroenterol Hepatol 2012; 10: 657-63.
8. Poynard T, Munteanu M, Deckmyn O, et al,. Applicability and precautions of use of liver injury biomarker FibroTest. A reappraisal at 7 years of age. BMC Gastroenterol 2011; 11: 39.
9. Poynard T, de Ledinghen V, Zarski JP, et al,. FibroTest and Fibroscan performances revisited in patients with chronic hepatitis C. Impact of the spectrum effect and the applicability rate. Clin Res Hepatol Gastroenterol 2011; 35: 720-30.